Tonix Pharmaceuticals Holding (NASDAQ: TNXP) — Company Overview, News & Financial Data
Tonix Pharmaceuticals develops innovative medicines for CNS disorders and rare diseases, aiming to meet significant unmet medical needs.
Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals (NASDAQ:TNXP) is a research-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to improve the lives of patients suffering from central nervous system (CNS) disorders, immunology, rare diseases, and infectious diseases. Dedicated to addressing unmet medical needs, Tonix Pharmaceuticals is actively engaged in developing a diverse portfolio of potential therapeutic solutions. Their projects range from preclinical to phase 3 clinical trials, with objectives to provide groundbreaking treatments for conditions lacking effective medications. The company's mission is to advance healthcare by delivering accessible, effective solutions to those in need, underscoring their commitment to innovation and patient care.
Snapshot
Operations
Products and/or services of Tonix Pharmaceuticals Holding
- TNX-102 SL - A sublingual tablet designed for the management of fibromyalgia and PTSD symptoms.
- TNX-1800 - A live replicating vaccine being developed for the prevention of COVID-19.
- TNX-1900 - A potential treatment for chronic migraine prevention, utilizing intranasal administration.
- TNX-1300 - A biologic designed to treat cocaine intoxication by breaking down cocaine in the blood.
Tonix Pharmaceuticals Holding executive team
- Seth LedermanCo-Founder, Interim Chief Medical Officer, President, CEO & Chairman
- Bradley SaengerCFO & Treasurer
- Jessica Edgar MorrisChief Operating Officer
- Gregory M. SullivanSecretary
- Siobhan FogartyChief Technical Officer
- Irina IshakGeneral Counsel
- Darryl RideoutExecutive Vice President of Experimental Chemistry
- Sina BavariExecutive Vice President of Infectious Disease Research & Development
- Zeil RosenbergExecutive Vice President of Medical
- Thomas EngleseChief Commercial Officer
Latest news about Tonix Pharmaceuticals Holding
Tonix enrolls first patient in depression trial
United StatesTonix claims data highlight high economic, medical burden of fibromyalgia
United StatesTonix outlines late-stage development path for long-acting Lyme disease antibody
United StatesTonix Pharmaceuticals licenses selective sigma-1 antagonist TNX-4900
United States
Key financials
Reported results for Tonix Pharmaceuticals Holding , in USD.
- Market cap
- 88.3M
- Revenue (TTM)
- 29.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -13.2
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 13.1M | -125.7M | -124M | |
| 10.1M | -136.7M | -130M | |
| 7.8M | -118.4M | -116.7M | |
| 9M | -112.1M | -115M |